Cite
HARVARD Citation
Harter, P. et al. (n.d.). 2022-RA-1074-ESGO AGO-OVAR 2.29 (ENGOT-ov34): atezolizumab in combination with bevacizumab and chemotherapy vs bevacizumab and chemotherapy in recurrent ovarian cancer. International journal of gynecological cancer. pp. A294-A295. [Online].